LONDON (dpa-AFX) - GSK plc (GSK, GSK.L) reported longer-term results from the phase II supported collaborative study with Memorial Sloan Kettering Cancer Center evaluating Jemperli or dostarlimab as a first-line treatment-as an alternative to surgery-for mismatch repair deficient locally advanced rectal cancer. The trial showed 100% clinical complete response rate in 42 patients who completed treatment with dostarlimab.
Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D, GSK, said: 'We look forward to evaluating dostarlimab in certain colorectal cancers in our ongoing AZUR-1 and AZUR-2 registrational studies.'
For More Such Health News, visit rttnews.com.
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2024 AFX News
